| scholarly article | Q13442814 |
| P2093 | author name string | Esther Fernández | |
| Esperanza Herreros | |||
| Alan T Hudson | |||
| Clive L Yeates | |||
| Domingo Gargallo-Viola | |||
| Edward C Capon | |||
| Federico Gómez de las Heras | |||
| Helen Trimming | |||
| James Woolven | |||
| Jesús Chicharro | |||
| John F Batchelor | |||
| José M Bueno | |||
| José M Fiandor | |||
| María L León | |||
| Mary Pudney | |||
| Mitch Fry | |||
| Neil J Cheesman | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| P304 | page(s) | 2845-2852 | |
| P577 | publication date | 2008-04-09 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials | |
| P478 | volume | 51 |
| Q24757085 | 4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities |
| Q35563452 | A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor |
| Q38116034 | Animal models of efficacy to accelerate drug discovery in malaria |
| Q35031417 | Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1 |
| Q51050573 | Atom-Economic Synthesis of 4-Pyrones from Diynones and Water. |
| Q42390524 | Bis{(E)-3-[(diethyl-methyl-ammonio)meth-yl]-N-[3-(N,N-dimethyl-sulfamo-yl)-1-methyl-pyridin-4-yl-idene]-4-methoxy-anilinium} tetra-iodide penta-hydrate |
| Q60923011 | Classical QSAR and Docking Simulation of 4-Pyridone Derivatives for Their Antimalarial Activity |
| Q48018699 | Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies. |
| Q39605132 | Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance |
| Q33599811 | Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers |
| Q38066994 | Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1. |
| Q56351367 | Functional screening of selective mitochondrial inhibitors of Plasmodium |
| Q35991425 | Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria |
| Q35958086 | Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). |
| Q24651549 | Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes |
| Q52857773 | Isoxazole mediated synthesis of 4-(1H)pyridones: improved preparation of antimalarial candidate GSK932121. |
| Q35776338 | Metal-free arylation of ethyl acetoacetate with hypervalent diaryliodonium salts: an immediate access to diverse 3-aryl-4(1H)-quinolones |
| Q37278195 | Mitochondria in malaria and related parasites: ancient, diverse and streamlined. |
| Q37615897 | New medicines to improve control and contribute to the eradication of malaria |
| Q37093155 | New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections |
| Q34525226 | Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium |
| Q35139464 | Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model |
| Q34334269 | Quinolone-3-diarylethers: a new class of antimalarial drug. |
| Q38379720 | Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria |
| Q56403247 | Recent updates in the discovery and development of novel antimalarial drug candidates |
| Q49330155 | Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA. |
| Q38018392 | Small molecule anti-malarial patents: a review (January 2010-June 2011). |
| Q33567066 | Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum |
| Q33606046 | Subnanomolar inhibitor of cytochrome bc1 complex designed by optimizing interaction with conformationally flexible residues |
| Q35168943 | Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum |
| Q35751097 | Synthesis of the cyanobacterial metabolite nostodione A, structural studies and potent antiparasitic activity against Toxoplasma gondii |
| Q46187258 | Synthesis, characterization, and antimicrobial evaluation of novel 5-benzoyl-N-substituted amino- and 5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridones. |
| Q39306287 | Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era. |
| Q56994500 | The development of quinoloneesters as novel antimalarial agents targeting the Plasmodium falciparum bc1protein complex |
| Q37464688 | The global portfolio of new antimalarial medicines under development. |
| Q35877970 | Tyrosine triad at the interface between the Rieske iron-sulfur protein, cytochrome c1 and cytochrome c2 in the bc1 complex of Rhodobacter capsulatus. |
| Q90914855 | Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease |
Search more.